FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2903751054> ?p ?o ?g. }

• W2903751054 endingPage "3037" @default.
• W2903751054 startingPage "3037" @default.
• W2903751054 abstract "Abstract Background Myelofibrosis (MF) is a myeloproliferative neoplasm (MPN) characterised by the frequent presence of driver mutations in genes causing activation of JAK2 signalling pathways (JAK2, CALR and MPL). Additional mutations affecting epigenetic regulators and splicing machinery are common. Anaemia with RBC-transfusion-dependence is common in patients with advanced myelofibrosis and represents a major unmet need. The RESUME study assessed the rates of RBC-transfusion independence (TI) after therapy with Pomalidomide (POM) vs placebo in persons with MPN-associated myelofibrosis and RBC-transfusion dependence. 16% of patients in both the POM and placebo arms became TI. Aims The genetic landscape of strictly confirmed transfusion dependent MF is not fully characterised. Our aim was to analyse the genetics of transfusion-dependent myelofibrosis patients in the RESUME trial and correlate with clinical characteristics, outcome and therapy response. Methods DNA samples were available from 207 of 252 patients and analysed by targeted re-sequencing using a Fluidigm Access Array gene panel followed by next generation sequencing. The panel included JAK2, CALR, MPL, TET2, ASXL1, EZH2, DNMT3A, IDH1/2, CBL, IKZF1, U2AF1, CHEK2, TP53, SF3B1, SRSF2, SH2B3, BARD1, DAP3, HRAS, IRF4, KRAS, KIT, Mir662, NFE2, POLG, SCRIB, SETBP1, TCF12 and VPS45. Results 97% (95-99%) of subjects had a mutation in ≥1 targeted gene. 2 mutations were detected in 41% (34-48%) and ≥3 in 27% (21-33%). 7 had no detectable mutation. Mutations in JAK2V617F, CALR and MPL were identified in 66% (59-72%), 14% (8-19%) and 7% (4-11%) of subjects (Figure 1), with no driver mutation in 27 patients (13%; 9-18%) (triple-negative). 68% (61-74%) had additional non-driver mutations. 42% (35-48%) (N=86) had spliceosome mutations (U2AF1 [21%]; SF3B1 [11%]; SRSF2 [8%]; ZRSR2; [6%]). More spliceosome mutations were detected in men than women (47% [39-55%] vs 27% [15-40%]; p=0.009). Spliceosome mutations were mutually exclusive in 83 subjects and were less common in subjects with prior polycythaemia vera (17% [5-37%]) compared with prior essential thrombocythaemia (39% [22-58%]) and primary MF (46% [38-54%]; p=0.024). Mutations in epigenetic regulators (ASXL1, 28%; TET2, 8%; DNMT3A 5%; EZH2 4%) were detected at similar rates to those previously reported. High molecular risk (HMR) mutations (ASXL1, EZH2, IDH1/2, SRSF2) were detected in 36% [29-43%] of subjects. Only 10 of 105 subjects with an epigenetic regulator gene mutation had ≥1 related mutation. Subjects with JAK2V617F were significantly more likely than subjects with a CALR mutation to have: (1) ≥1 additional mutation (72% [64-79%] vs. 35% [18-54%], p=0.0001); (2) a spliceosome mutation (44% [36-53%] vs. 17% [6-36%], p=0.07), in particular a U2AF1 mutation (24% [17-32%] vs. 0%; p=0.004) and (3) a HMR mutation (38% [30-47%] vs. 21% [8-40%]; p=0.07). Survival at 1.5 years was 62% (55-67%) and was not significantly associated with the presence or number of mutations in this uniformly high-risk cohort. Survival in subjects without an SF3B1 mutation was better than those SF3B1-mutated (80% [56-91%]) vs. 59% [52-65%]; p=0.07). Driver mutation status did not influence the probability of achieving red blood cell (RBC) TI, regardless of therapy. Additional non-driver mutations were more often detected in those failing to achieve RBC-TI than those achieving RBC-TI (70% [63-77%] vs 56% [40-71%], p=0.07). Furthermore, those with additional non-driver mutations were less likely to achieve ≥50% reduction in RBC transfusions (24% [17-32%] vs. 39% [27-51%]; p=0.03). A significant correlation persisted in subjects receiving POM but not in those receiving placebo. There was also a significant correlation between U2AF1 mutations and RBC-TI in POM treated subjects compared with controls; U2AF1-mutated subjects were less likely to achieve RBC-TI (3% [1, 17%]) than U2AF1-unmutated subjects (25% [17, 34%], p=0.008). No other mutations were significantly correlated with response. Conclusion We found a high incidence of spliceosome mutations in persons with MPN-associated MF and RBC-transfusion-dependence. Mutation of U2AF1 correlated with response in subjects receiving POM but not in those receiving placebo. Incorporation of mutation profiling into clinical trial design may help to inform subgroups of patients that may benefit from the intervention. Disclosures Devos: Novartis: Consultancy; Celgene: Consultancy; Takeda: Consultancy. Gisslinger:Shire: Consultancy, Honoraria; Novartis: Honoraria, Research Funding; AOP Orphan Pharmaceuticals AG: Consultancy, Honoraria, Research Funding; Janssen Cilag: Consultancy, Honoraria. Kiladjian:Celgene: Membership on an entity's Board of Directors or advisory committees; AOP Orphan: Membership on an entity's Board of Directors or advisory committees, Research Funding; Novartis: Membership on an entity's Board of Directors or advisory committees, Research Funding. Mesa:Celgene: Research Funding; UT Health San Antonio - Mays Cancer Center: Employment; Pfizer: Research Funding; Gilead: Research Funding; NS Pharma: Research Funding; CTI Biopharma: Research Funding; Incyte Corporation: Research Funding; Novartis: Consultancy; Promedior: Research Funding; Genentech: Research Funding. Ribrag:argenX: Research Funding; BMS: Consultancy, Honoraria, Other: travel; NanoString Technologies: Consultancy, Honoraria; pharmamar: Other: travel; Infinity: Consultancy, Honoraria; MSD: Honoraria; Amgen: Research Funding; Gilead: Consultancy, Honoraria; Servier: Consultancy, Honoraria; Roche: Honoraria, Other: travel; epizyme: Consultancy, Honoraria; Incyte Corporation: Consultancy. Schiller:Celator/Jazz Pharmaceuticals: Research Funding; Pharmacyclics: Research Funding. Vannucchi:Celgene: Membership on an entity's Board of Directors or advisory committees; ITALFARMACO: Membership on an entity's Board of Directors or advisory committees; Novartis: Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau. Reiser:Celgene: Employment. Zhong:Celgene: Employment. Mead:Novartis: Consultancy, Honoraria, Research Funding, Speakers Bureau; ARIAD: Consultancy; Bristol-Myers Squibb: Consultancy; Cell Therapeutics: Consultancy; Celgene: Research Funding; Elstar: Research Funding; Evotek: Research Funding." @default.
• W2903751054 created "2018-12-22" @default.
• W2903751054 creator A5003941928 @default.
• W2903751054 creator A5009381933 @default.
• W2903751054 creator A5016216479 @default.
• W2903751054 creator A5020219431 @default.
• W2903751054 creator A5025797543 @default.
• W2903751054 creator A5032462496 @default.
• W2903751054 creator A5037299848 @default.
• W2903751054 creator A5039057642 @default.
• W2903751054 creator A5040279871 @default.
• W2903751054 creator A5042139474 @default.
• W2903751054 creator A5042997904 @default.
• W2903751054 creator A5044506983 @default.
• W2903751054 creator A5046772202 @default.
• W2903751054 creator A5049331182 @default.
• W2903751054 creator A5051805198 @default.
• W2903751054 creator A5052596963 @default.
• W2903751054 creator A5053069175 @default.
• W2903751054 creator A5062534223 @default.
• W2903751054 creator A5072839097 @default.
• W2903751054 creator A5075775681 @default.
• W2903751054 creator A5088486180 @default.
• W2903751054 creator A5089433535 @default.
• W2903751054 creator A5091536542 @default.
• W2903751054 date "2018-11-29" @default.
• W2903751054 modified "2023-09-27" @default.
• W2903751054 title "Spliceosome Mutations Are Common in MPN-Associated Myelofibrosis with RBC-Transfusion-Dependence and Correlate with Response to Pomalidomide" @default.
• W2903751054 doi "https://doi.org/10.1182/blood-2018-99-119402" @default.
• W2903751054 hasPublicationYear "2018" @default.
• W2903751054 type Work @default.
• W2903751054 sameAs 2903751054 @default.
• W2903751054 citedByCount "0" @default.
• W2903751054 crossrefType "journal-article" @default.
• W2903751054 hasAuthorship W2903751054A5003941928 @default.
• W2903751054 hasAuthorship W2903751054A5009381933 @default.
• W2903751054 hasAuthorship W2903751054A5016216479 @default.
• W2903751054 hasAuthorship W2903751054A5020219431 @default.
• W2903751054 hasAuthorship W2903751054A5025797543 @default.
• W2903751054 hasAuthorship W2903751054A5032462496 @default.
• W2903751054 hasAuthorship W2903751054A5037299848 @default.
• W2903751054 hasAuthorship W2903751054A5039057642 @default.
• W2903751054 hasAuthorship W2903751054A5040279871 @default.
• W2903751054 hasAuthorship W2903751054A5042139474 @default.
• W2903751054 hasAuthorship W2903751054A5042997904 @default.
• W2903751054 hasAuthorship W2903751054A5044506983 @default.
• W2903751054 hasAuthorship W2903751054A5046772202 @default.
• W2903751054 hasAuthorship W2903751054A5049331182 @default.
• W2903751054 hasAuthorship W2903751054A5051805198 @default.
• W2903751054 hasAuthorship W2903751054A5052596963 @default.
• W2903751054 hasAuthorship W2903751054A5053069175 @default.
• W2903751054 hasAuthorship W2903751054A5062534223 @default.
• W2903751054 hasAuthorship W2903751054A5072839097 @default.
• W2903751054 hasAuthorship W2903751054A5075775681 @default.
• W2903751054 hasAuthorship W2903751054A5088486180 @default.
• W2903751054 hasAuthorship W2903751054A5089433535 @default.
• W2903751054 hasAuthorship W2903751054A5091536542 @default.
• W2903751054 hasBestOaLocation W29037510541 @default.
• W2903751054 hasConcept C126322002 @default.
• W2903751054 hasConcept C143998085 @default.
• W2903751054 hasConcept C2776364478 @default.
• W2903751054 hasConcept C2777478702 @default.
• W2903751054 hasConcept C2778524551 @default.
• W2903751054 hasConcept C2780007613 @default.
• W2903751054 hasConcept C2780076729 @default.
• W2903751054 hasConcept C2781107747 @default.
• W2903751054 hasConcept C502942594 @default.
• W2903751054 hasConcept C71924100 @default.
• W2903751054 hasConceptScore W2903751054C126322002 @default.
• W2903751054 hasConceptScore W2903751054C143998085 @default.
• W2903751054 hasConceptScore W2903751054C2776364478 @default.
• W2903751054 hasConceptScore W2903751054C2777478702 @default.
• W2903751054 hasConceptScore W2903751054C2778524551 @default.
• W2903751054 hasConceptScore W2903751054C2780007613 @default.
• W2903751054 hasConceptScore W2903751054C2780076729 @default.
• W2903751054 hasConceptScore W2903751054C2781107747 @default.
• W2903751054 hasConceptScore W2903751054C502942594 @default.
• W2903751054 hasConceptScore W2903751054C71924100 @default.
• W2903751054 hasIssue "Supplement 1" @default.
• W2903751054 hasLocation W29037510541 @default.
• W2903751054 hasOpenAccess W2903751054 @default.
• W2903751054 hasPrimaryLocation W29037510541 @default.
• W2903751054 hasRelatedWork W1964737346 @default.
• W2903751054 hasRelatedWork W2073011666 @default.
• W2903751054 hasRelatedWork W2090253116 @default.
• W2903751054 hasRelatedWork W2148751534 @default.
• W2903751054 hasRelatedWork W2167820983 @default.
• W2903751054 hasRelatedWork W2534149640 @default.
• W2903751054 hasRelatedWork W2538768056 @default.
• W2903751054 hasRelatedWork W2903749170 @default.
• W2903751054 hasRelatedWork W3040782867 @default.
• W2903751054 hasRelatedWork W4249546999 @default.
• W2903751054 hasVolume "132" @default.
• W2903751054 isParatext "false" @default.
• W2903751054 isRetracted "false" @default.
• W2903751054 magId "2903751054" @default.
• W2903751054 workType "article" @default.